Psychedelics as Transformative Therapeutics.
Bryan L. Roth, Ryan H. Gumpper
American Journal of Psychiatry May 1, 2023 DOI: 10.1176/appi.ajp.20230172 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Hallucinogenic drugs Pharmacokinetics Psychedelics Psychopharmacology |
| Citations | 55 |
| Key findings | Psychedelics have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions, and understanding their biological mechanisms and potential pitfalls is imperative. |
Abstract
Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most of the basic science has utilized these compounds as probes to interrogate various endogenous neurotransmitter systems-mainly the serotonin 5-HT2A receptor. With the renewed interest in utilizing these compounds as therapeutics and the explosion in clinical trials, psychedelics have been purported to treat many neuropsychiatric disorders, including depression, cluster headaches, migraines, anxiety, and obsessive-compulsive disorder. It is therefore imperative to understand the biology and pharmacology behind their therapeutic mechanisms as well as expose any potential pitfalls in their widespread use as treatments. This review covers the latest advances in understanding the biological mechanisms, the newest efforts in drug discovery, and potential pitfalls when it comes to utilizing this class of compounds as emerging therapeutics.
Citations in the library
Cited by 41
- Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? European Archives of Psychiatry and Clinical Neuroscience February 27, 2024
- Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states. Science November 15, 2024
- A Brief Historical Overview of Psychedelic Research. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging May 1, 2024
- Stimulant and hallucinogenic novel psychoactive substances; an update Expert Review of Clinical Pharmacology November 2, 2023
- Psilocybin for the treatment of Alzheimer’s disease Frontiers in Neuroscience July 10, 2024
and 36 more in the library
Cites 53
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
and 48 more in the library